1. Home
  2. SPTX vs QURE Comparison

SPTX vs QURE Comparison

Compare SPTX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seaport Therapeutics Inc. Common Stock

SPTX

Seaport Therapeutics Inc. Common Stock

N/A

Current Price

$21.25

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$42.67

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPTX
QURE
Founded
N/A
1998
Country
United States
Netherlands
Employees
N/A
248
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2026
2013

Fundamental Metrics

Financial Performance
Metric
SPTX
QURE
Price
$21.25
$42.67
Analyst Decision
Buy
Analyst Count
0
14
Target Price
N/A
$45.00
AVG Volume (30 Days)
206.6K
2.9M
Earning Date
N/A
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.67
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
N/A
$126.12
Revenue Next Year
N/A
$200.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.59
$8.73
52 Week High
$22.98
$71.50

Technical Indicators

Market Signals
Indicator
SPTX
QURE
Relative Strength Index (RSI) 62.35 58.82
Support Level $17.89 $21.63
Resistance Level $21.59 $50.47
Average True Range (ATR) 1.88 3.04
MACD 0.06 -0.83
Stochastic Oscillator 68.80 30.86

Price Performance

Historical Comparison
SPTX
QURE

About SPTX Seaport Therapeutics Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Share on Social Networks: